Effects of intranasal oxytocin on satiety signaling in people with schizophrenia
| Autor: | Charlene Chester, Deanna L. Kelly, Kimberly R. Warren, Robert P. McMahon, Shuo Chen, Fang Liu, Heidi J. Wehring |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Blood Glucose Leptin Male medicine.medical_specialty Time Factors Adolescent medicine.medical_treatment Experimental and Cognitive Psychology Satiation Overweight Oxytocin Placebo Eating Young Adult 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Double-Blind Method Internal medicine Appetite Depressants medicine Humans Insulin Administration Intranasal Cross-Over Studies business.industry Middle Aged medicine.disease Obesity 030227 psychiatry Smell Endocrinology Schizophrenia Taste Female Schizophrenic Psychology medicine.symptom business 030217 neurology & neurosurgery Psychopathology medicine.drug |
| Zdroj: | Physiology & Behavior. 189:86-91 |
| ISSN: | 0031-9384 |
| Popis: | Overweight and obesity in schizophrenia are prevalent, affecting half to three-quarters of people with schizophrenia. Hyperphagia and increased meal size have also been implicated as significant contributors to the weight gain problem. Oxytocin has shown to play a role in appetite control in humans and is considered an anorexigenic peptide. This two-day, within-subjects, challenge study involved the examination of satiety after administration of 24 IU oxytocin (intranasal) vs. placebo in participants with a DSM-IV diagnosis of schizophrenia (N = 16). Self reported satiety along with a preload-test meal paradigm were utilized as well as related laboratory measures (insulin, glucose, and leptin), and measures of taste and smell. There were no statistically significant differences between the groups on self-reported satiety or test meal consumption, insulin or glucose levels, or sensory measures. A significant treatment difference was found (F = 5.22, df = 1,97.6, p = 0.025), with a decrease in leptin in the oxytocin group post-administration, but no time effect (F = 1.67, df = 6,95.1, p = 0.180) or treatment by time interaction (F = 1.36. df = 3,4.16, p = 0.261). Despite the small sample and mostly negative findings, we encourage more work to use higher and repeated doses of oxytocin, and to further examine the effect of oxytocin on leptin in schizophrenia as this may be important for understanding both weight control and psychopathology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect